GlassScriptPhysician profile
Mary Oliver
NPI 1952546954
$1,987.98
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $339 · 2023: $827 · 2024: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $339.66 | 2022-2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.76 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $210.23 | 2023 | Ingrezza |
| Abbvie INC. | $172.58 | 2023-2024 | |
| Argenx US, INC. | $131.71 | 2023 | Vyvgart |
| Insmed, INC. | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.86 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $117.77 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $115.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $106.34 | 2024 | Fanapt |
| Sobi, INC | $86.95 | 2023 | |
| Boston Scientific Corporation | $80.31 | 2021 | |
| Alkermes, INC. | $37.35 | 2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $18.84 | 2023 | Uzedy |
| Indivior INC. | $15.62 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.